Biodesix, Inc. (BDSX) Earnings Call Analysis

NASDAQ · Healthcare · Diagnostics & Research

21/25

Growth 5 Margin 5 Expansion 4 Platform 4 Financial 3

latest quarter score

Earnings Reports

21
BioDesix (BDSX) Q2 2026: Diagnostic Test Volumes Surge 38% as Primary Care Expansion Drives Adoption
August 06, 2026
19
Biodesic (BDSX) Q1 2026: Diagnostic Test Volumes Jump 29% as Primary Care Channel Expands Reach
June 16, 2026
15
Biodesix (BDSX) Q2 2025: Development Services Revenue Jumps 53% as Primary Care Push Gains Traction
June 16, 2026
20
Biodesics (BDSX) Q3 2025: Primary Care Test Orders Jump 75% as Sales Expansion Drives Adoption
June 16, 2026
18
Biodesix (BDSX) Q4 2025: Lung Diagnostics Revenue Jumps 46% as Primary Care Channel Expands
June 15, 2026
19
BDSX Q4 2024: Diagnostic Development Services Revenue Jumps 70%, Expanding Multimodal Growth Path
July 06, 2025
20
BDSX Q1 2025: Sales Rep Count Drops 8%, Delaying Primary Care Expansion and Revenue Ramp
July 06, 2025
Biodesix (BDSX) Q3 2024: Lung Diagnostic Revenue Climbs 40% as Sales Force Expansion Reignites Growth Trajectory
November 01, 2024
BDSX Q2 2024: Biopharma Services Revenue Jumps 228% as Lung Diagnostics Scales
August 07, 2024
Biodesix (BDSX) Q1 2024: Lung Diagnostic Test Volume Up 57%, Margin Leverage Signals Profit Path
May 08, 2024
Biodesix (BDSX) Q4 2023: Lung Test Volumes Surge 65% as Margin Expansion Accelerates
March 01, 2024
17
Biodesix (BDSX) Q3 2023: Lung Test Volumes Surge 60%, Margin Leverage Accelerates Path to Profitability
November 07, 2023
Biodesix (BDSX) Q2 2023: Core Lung Diagnostics Revenue Surges 58% as Test Volumes Hit Record Highs
August 07, 2023
BDSX Q1 2023: Core Lung Diagnostics Revenue Soars 86%, Margin Expansion Signals Path to Profitability
May 11, 2023
Biodesix (BDSX) Q4 2022: Core Lung Diagnostics Revenue Jumps 57% as Test Adoption Accelerates
March 06, 2023

Browse all companies